(Q55056989)

16 June 2018

title

Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. (English)

1 reference

16 June 2018

acute generalized exanthematous pustulosis

main subject

0 references

author

Alexander Navarini

1

1 reference

16 June 2018

Jonathan N. Barker

4

1 reference

16 June 2018

Francesca Capon

5

1 reference

16 June 2018

Peggy Sekula

8

1 reference

16 June 2018

Richard C Trembath

10

1 reference

16 June 2018

Catherine H Smith

12

1 reference

16 June 2018

Michael Simpson

Michael A Simpson

9

0 references

Niovi Setta-Kaffetzi

3

Niovi Setta-Kaffetzi

1 reference

16 June 2018

Maja Mockenhaupt

11

Maja Mockenhaupt

1 reference

16 June 2018

Laurence Valeyrie-Allanore

2

Laurence Valeyrie-Allanore

1 reference

16 June 2018

Jean-Claude Roujeau

7

Jean-Claude Roujeau

1 reference

16 June 2018

author name string

Daniel Creamer

6

1 reference

16 June 2018

language of work or name

English

0 references

publication date

28 January 2013

1 reference

16 June 2018

Journal of Investigative Dermatology

published in

1 reference

16 June 2018

volume

133

1 reference

16 June 2018

issue

7

1 reference

16 June 2018

page(s)

1904-1907

1 reference

16 June 2018

A method and server for predicting damaging missense mutations

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Pharmacogenetics in clinical dermatology

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Acute generalized exanthematous pustulosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Immune self-reactivity triggered by drug-modified HLA-peptide repertoire

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Ecthymatous skin eruption during therapy with cetuximab.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Phenotype standardization for immune-mediated drug-induced skin injury.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR).

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Generalized pustular psoriasis or drug-induced toxic pustuloderma? The use of patch testing

1 reference

https://api.crossref.org/works/10.1038%2FJID.2013.44

7 January 2021

Identifiers

DOI

10.1038/JID.2013.44

1 reference

16 June 2018

Dimensions Publication ID

1021712167

0 references

1 reference

16 June 2018